Higher Vedolizumab Clearance Associates with Poor Therapeutic Outcomes during Intravenous Vedolizumab Maintenance Therapy in Crohn’s Disease
Lay Summary Vedolizumab clearance (CL) outperforms serum trough concentrations in predicting therapeutic outcomes in Crohn’s disease. Higher CL was significantly associated with reduced remission rates, supporting CL as a pharmacokinetic marker for optimizing vedolizumab therapy.
Authors
- Mark Löwenberg (ORCID: https://orcid.org/0000-0002-4975-9945)
- Severine A.R.A. Vermeire (ORCID: https://orcid.org/0000-0001-9942-3019)
- Peter Bossuyt (ORCID: https://orcid.org/0000-0003-4027-7365)
- Frank Hoentjen (ORCID: https://orcid.org/0000-0001-5314-4452)
- John C. Panetta (ORCID: https://orcid.org/0000-0003-1308-7208)
- Geert D’Haens (ORCID: https://orcid.org/0000-0003-2784-4046)
- Thierry Dervieux (ORCID: https://orcid.org/0000-0002-3799-4438)
- Suzanne I. Anjie (ORCID: https://orcid.org/0000-0002-3599-3618)
- Tamás Molnár (ORCID: https://orcid.org/0000-0002-4913-7599)
- Esmé Clasquin
- Filip Baert
Institutions
- St. Jude Children's Research Hospital (US)
- Radboud University Nijmegen (NL)
- University of Alberta (CA)
- University of Szeged (HU)
- University of Alberta Hospital (CA)
- Radboud University Medical Center (NL)
- Prometheus Biosciences (United States) (US)
- Imelda Hospital (BE)
- AZ Delta (BE)
- Amsterdam University Medical Centers (NL)
- KU Leuven (BE)
Publication Details
- Journal
- Inflammatory Bowel Diseases
- Published
- 2025-11-10
- DOI
- https://doi.org/10.1093/ibd/izaf255
- Primary Topic
- Inflammatory Bowel Disease
- Type
- article
- Field-Weighted Citation Impact
- 0.00